News

Healthline2y
All About Libtayo
If you have a certain kind of skin or lung cancer, your doctor may recommend Libtayo to treat your condition. Libtayo is a prescription medication that’s used in adults to treat the following ...
WebMD7mon
How Libtayo Works for Non-Small-Cell Lung Cancer
If your cancer responds to the medicine, you will receive Libtayo infusions for up to 24 months (two years). If your cancer grows or spreads, or you have certain side effects, you may stop using ...
Nasdaq2y
Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer
Your healthcare provider may also need to delay or completely stop treatment with Libtayo if you have severe side effects. Before you receive Libtayo, tell your healthcare provider about all your ...
FOX40 News2y
Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)
Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects. Before you receive Libtayo, tell your healthcare provider about all your ...
Seeking Alpha4mon
Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects. Before you receive LIBTAYO, tell your healthcare provider about all ...
Cancer Research UK2y
Targeted drugs and immunotherapy for skin cancer
Cemiplimab (Libtayo) is a type of immunotherapy called a checkpoint ... Everyone is different and the side effects vary from person to person. The side effects you have depend on: which drug you have ...
Cure Today2y
Second-Line Treatment With Libtayo May Improve Long-Term Survival in Subset of Patients With Cervical Cancer
Treatment with Libtayo may improve survival over a 30-month period with no new side effects in patients with recurrent or metastatic cervical cancer, opening the doors for an immunotherapy option for ...
Finanznachrichten1y
Regeneron Pharmaceuticals, Inc.: Libtayo (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell ...
Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects. Before you receive LIBTAYO, tell your healthcare provider about all your ...
Morningstar27d
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
“Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has ...
KRON4 News2y
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Your healthcare provider may also need to delay or completely stop treatment with Libtayo if you have severe side effects. Before you receive Libtayo, tell your healthcare provider about all your ...
Yahoo Finance2y
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Specifically, the CHMP recommended the Libtayo combination be approved in the European Union (EU) for first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC ...